Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
The Macfarlane Burnet Institute for Medical Research and Public Health Ltd.
| The Macfarlane Burnet Institute for Medical Research and Public Health Ltd. Patent applications | ||
| Patent application number | Title | Published |
|---|---|---|
| 20120064528 | METHODS AND REAGENTS FOR QUANTIFYING NUCLEIC ACID FRAGMENTATION AND APOPTOSIS (QLM-PCR, CELL NUMBER QPCR AND APOQPCR) - A method for quantifying apoptosis in absolute terms in a cellular sample by real-time ligation-mediated PCR, the method comprising: (a) obtaining first control genomic nucleic acid which is apoptotic nucleic acid from a cellular sample that is substantially 100% apoptotic; (b) obtaining test genomic nucleic acid derived from a test cellular sample; (c) subjecting a plurality of different known concentrations of first control genomic nucleic acid to real-time apoptosis-specific multi-product PCR in the presence of a nucleic acid-binding fluorophore or other detectable tag to obtain a threshold cycle number (Ct) or other equivalent value at different nucleic acid concentrations and establishing a linear numerical relationship between Ct or equivalent value and apoptotic nucleic acid concentration; (d) subjecting test nucleic acid to real-time apoptosis-specific multi-product PCR in the presence of a nucleic acid-binding fluorophore or other detectable tag to obtain a Ct or other equivalent value; and (e) establishing the quantity of apoptotic nucleic acid in the test nucleic acid, which corresponds numerically to the concentration of nucleic acid in (c) which determines the Ct or equivalent value obtained in (d). A standard composition of isolated genomic nucleic acid comprising substantially 100% apoptotic nucleic acid or comprising apoptotic nucleic acid as a predetermined proportion of an isolated nucleic acid sample. A kit comprising same. | 03-15-2012 |
| 20100119514 | Antibodies Against Cancer - An isolated binding partner of a Cripto-1 protein, Pim-1 protein or an antigen present in a colon cancer cell lysate is described. The binding partner inhibits growth of one or more cancer cell types and may be used in an anti-cancer agent for treating cancer in a subject. The binding partner may also be used in a method of inducing apoptosis in a cancer cell, as well as in a method of sensitising a cancer cell to a cytotoxic compound. In addition, a cancer vaccine is described wherein the vaccine comprises a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate or, alternatively, comprises an expressible DNA molecule encoding a Cripto-1 protein (or an antigenic fragment thereof), Pim-1 protein (or an antigenic fragment thereof) or an antigen present in a colon cancer cell lysate. | 05-13-2010 |